Kidney Cancer Trial, Recruiting NCT07657325 Sponsor: Tianjin Medical University Second Hospital Condition: Kidney Cancer
Back to Kidney Cancer

Kidney Cancer Trial, Recruiting

NCT07657325
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with a type of kidney cancer called renal cell carcinoma (with or without certain tissue features), confirmed by a laboratory test on a tissue sample.
  • People who are at least 18 years old at the time of signing the consent form.
  • People who are willing and able to provide written consent to participate before the trial begins.
  • People whose kidney cancer is classified as either high-risk (based on how far the tumour has spread to surrounding tissue or nearby lymph nodes, but not to distant parts of the body) or as "M1 NED" (meaning the cancer had spread to one separate area of soft tissue outside the kidney, but all visible cancer was completely removed during surgery).
  • People who have not previously received any systemic (whole-body) treatment for advanced kidney cancer, other than surgery to remove the kidney or part of the urinary system.
  • People who have had the kidney surgically removed (and, if applicable, all other affected tissue removed) with clean surgical margins, meaning no cancer cells were detected at the edges of the removed tissue.
  • People who have been assessed by the trial doctor as cancer-free, confirmed by a CT or MRI scan, with no signs of cancer in the brain.
  • People whose general physical functioning is rated as 0 or 1 on a standard medical scale, meaning they are either fully active or have only minor limitations in physically demanding activity.
  • Women of childbearing potential who agree to use an approved form of contraception during treatment and for 3 months after treatment ends, test negative for pregnancy within 7 days before enrolment, and are not breastfeeding. Men of reproductive potential who agree to use an approved form of contraception with their partner during treatment and for 3 months after treatment ends.
  • People whose blood, kidney, and liver function results fall within the levels required by the trial (confirm with trial site for exact values).

Who may not be able to join:

  • People who have previously received systemic drug treatments for advanced kidney cancer (surgery to remove the kidney is the only prior treatment that may be acceptable).
  • People whose surgery did not achieve clean margins, meaning cancer cells were found at the edges of the removed tissue.
  • People whose scans show remaining signs of cancer, or who have suspected cancer spread to the brain.
  • People whose physical functioning is rated lower than 1 on the standard medical scale, meaning their daily activity is significantly limited.
  • Women who are pregnant or breastfeeding, or who are unwilling or unable to use approved contraception during and after the treatment period.
  • People whose blood counts, kidney function, or liver function do not meet the minimum levels required by the trial (confirm with trial site for exact values).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 13388067990

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tianjin Medical University Second Hospital
Registry
ClinicalTrials.gov
Start date
1 April 2024
Est. completion
1 February 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Effect on the disease-free survival in the trial patients.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov